ESI-GROUP
8.6.2021 14:02:09 CEST | Business Wire | Press release
Regulatory News:
ESI Group (Paris:ESI), a global player in virtual prototyping for industries, participates in the successful development phase of the Nivus made by Volkswagen do Brazil: 100% digitally and virtually – a world premiere. The process began before the pandemic and was completed during the COVID-19 period, applying all the sanitary measures in place. Thanks to Virtual Prototyping/Digital Development (a change in product development), time was shortened in about 10 months and saved a few million euros in prototype production costs: Would it be a shift in the industry?
Making the right decision, quickly and 100% digitally
Usually, when a new vehicle is developed, time and physical prototypes are required both during the design and assembly preparation phases. In the case of the Nivus, launched in a live broadcast by Volkswagen do Brazil in June 2020 to around 60 countries, the whole conception of the vehicle was made 100% virtually.
The state-of-the-art solution provided by ESI Group, based on its software IC.IDO
was one of the tools used to design reviews and engineering decisions in different departments (product development, operations, quality, etc). This allowed Volkswagen to make informed decisions regarding the car’s conception. It provided the automotive company with the opportunity to save time (shortened the car’s development in about 10 months) and investment (for example, only in the Virtual Prototype Laboratory there was a 65% reduction of costs compared to previous projects).
Virtual reality also conserves tons of paper, in which specifications for each part of a car were previously detailed.
Long before Nivus physically existed, the vehicle was already available digitally in the engineering computers. Considering that building a physical prototype takes 19 weeks, in which only a single vehicle variant is possible. For this vehicle, nine virtual variants were produced, in much less time, which made it possible to anticipate more efficient assembly procedures, reducing the number of processes in the simulations and avoiding errors, since all parts were previously tested with digital tools.
"We designed 100% of the Nivus with digital processes using, among others, ESI’s technology without the need to assemble a single physical prototype. In addition, with the drastic reduction of the development time, this solution helps us to integrate all our different teams, from various department (design, engineering, marketing, production, etc) in the same decision-making process. It was a more efficient but also more collaborative process. " explains Francisvaldo Gomes Aires, Prototyping Development Manager at Volkswagen do Brazil.
Virtual reality: A huge benefit during COVID-19
ESI demonstrated that even when the design phase is impacted, in this case by COVID-19, it is possible to continue with the project, since it is no longer a question of relying solely on physical reality. This opens up the possibility of experiencing the future with digitalization and technology for the project benefit.
“It’s a shift in the industrial production. For the first time, all phases of a car release, before the effective production, has been fully made virtually making the production feasible during Covid-19 time. While allowing Volkswagen to take all its design and manufacturing decisions virtually, we helped them produce faster, cheaper and in a more sustainable way. This was possible due to a strong support of our local Brazilian team and a mutual collaboration between ESI Brazil and Volkswagen do Brazil. We all feel proud to be part of this world-premiere alongside with Volkswagen and its partners.” declares Andreas Renner, Volkswagen Global Account Manager – ESI Group.
About ESI Group
Founded in 1973, ESI Group is a leading innovator in Virtual Prototyping solutions and a global enabler of industrial transformation. Thanks to the company’s unique know-how in the physics of materials, it has developed and refined, over the last 45 years, advanced simulation capabilities. Having identified gaps in the traditional approach to Product Lifecycle Management (PLM), ESI has introduced a holistic methodology centered on industrial productivity and product performance throughout its entire lifecycle, i.e. Product Performance Lifecycle™, from engineering to manufacturing and in operation. Present in more than 20 countries, and in major industrial sectors, ESI employs 1200 high level specialists around the world and reported 2020 sales of €132.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com .
Follow ESI
http://www.esi-group.com/linkedin
http://www.esi-group.com/facebook
http://www.esi-group.com/twitter
http://www.esi-group.com/youtube
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005672/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
